Company Overview and News

0
NCZ / AGIC Convertible & Income Fund II ALLIANZGI CONVERTIBLE & INCOME FUND II

9h sec.gov
AllianzGI Convertible & Income Fund II Table of Contents As filed with the Securities and Exchange Commission on August 15, 2018 1933 Act File No. 333-225290 1940 Act File No. 811-21338
NCZ

0
NCZ / AGIC Convertible & Income Fund II ALLIANZGI CONVERTIBLE & INCOME FUND II

2018-08-01 sec.gov
AllianzGI Convertible & Income Fund II As filed with the Securities and Exchange Commission on August 1, 2018 SECURITIES
NCZ

0
NCZ / AGIC Convertible & Income Fund II ALLIANZGI CONVERTIBLE & INCOME FUND II

2018-07-30 sec.gov
AllianzGI Convertible & Income Fund II As filed with the Securities and Exchange Commission on July 27, 2018 SECURITIES AND EXCHANGE COMMISSION
NCZ

0
NCZ / AGIC Convertible & Income Fund II ALLIANZGI CONVERTIBLE & INCOME FUND II

2018-07-23 sec.gov
AllianzGI Convertible & Income Fund II Table of Contents As filed with the Securities and Exchange Commission on July 20, 2018 1933 Act File No. 333-225290 1940 Act File No. 811-21338
NCZ

0
PHK: Can The High Yield Sustain That Hefty Premium?

2018-07-21 seekingalpha
I'll be following my overview of the PIMCO CEFs with closer looks at the individual funds.
ECCB PHK ECCA ECC NCZ ECCZ ECCY OXLC

0
NCZ / AGIC Convertible & Income Fund II ALLIANZGI CONVERTIBLE & INCOME FUND II (Quarterly Schedule of Portfolio Holdings)

2018-07-20 sec.gov
AllianzGI Convertible & Income Fund II UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington
NCZ

0
NCZ / AGIC Convertible & Income Fund II ALLIANZGI CONVERTIBLE & INCOME FUND II

2018-06-28 sec.gov
AllianzGI Convertible & Income Fund II As filed with the Securities and Exchange Commission on June 28, 2018 SECURITIES AND EXCHANGE COMMISSION
NCZ

22
151 Monthly Paying Dividend SML Equities And 69 Funds For June

2018-06-21 seekingalpha
Here's your June 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains reports. Nano-Cap MoPays are not listed.
SCA CCAOF "NHF" CJ CBL WSR CRLFF AD ALARF CRIUF ORC MHIVF OXLCO OXLCN SCM ATGFF SOT.UN CJR.B ECC AMZA ECCZ AGNC AHOTF ECCY PHK SRRTF QYLD PSEC OXLC ECCB NCV CJREF SCQ ECCA SUNS GNL NCZ NHF PBB SRT.UN

1
NCZ / AGIC Convertible & Income Fund II ALLIANZGI CONVERTIBLE & INCOME FUND II

2018-06-20 sec.gov
AllianzGI Convertible & Income Fund II As filed with the Securities and Exchange Commission on June 20, 2018 SECURITIES AND EXCHANGE COMMISSION
NCZ

0
NCZ / AGIC Convertible & Income Fund II ALLIANZGI CONVERTIBLE & INCOME FUND II

2018-05-30 sec.gov
AllianzGI Convertible & Income Fund II Table of Contents As filed with the Securities and Exchange Commission on May 30, 2018 1933 Act File No. 333-[ ] 1940 Act File No. 811-213
NCZ

0
NCZ / AGIC Convertible & Income Fund II ALLIANZGI CONVERTIBLE & INCOME FUND II

2018-05-01 sec.gov
AllianzGI Convertible & Income Fund II Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
NCZ

0
NCZ / AGIC Convertible & Income Fund II null

2018-04-23 sec.gov
PAGE 1 000 B000000 02/28/2018 000 C000000 0001227857 000 D000000 N 000 E000000 NF 000 F000000 Y 000 G000000 N 000 H000000 N 000 I000000 6.1 000 J000000 A 001 A000000 ALLIANZGI CONVERTIBLE & INCOME FUND II 001 B000000 811-21338 001 C000000 2127393371 002 A000000 1633 BROADWAY 002 B000000 NEW YORK 002 C000000 NY 002 D010000 10019 003 000000 N 004 000000 N 005 000000 N 006 000000 N 007 A000000 N 007 B000000 0 007 C010100 1 008 A000001 ALLIANZ GLOBAL INVESTORS U.
NCZ

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 018825109